Shares of Glenmark Pharmaceuticals (NSE: GLENMARK) are expected to be in focus today after the company announced the US launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC). The product, an alternative to the active ingredient in MiraLAX® Powder for Solution by Bayer HealthCare LLC, marks Glenmark’s expansion in the US over-the-counter (OTC) segment.
On March 7, 2025, Glenmark closed at ₹1,401.20, up 0.32%, after touching an intraday high of ₹1,415.00. The stock has gained traction following the launch, as investors anticipate growth in the US OTC business.
Market impact of the launch
According to Nielsen® data, the MiraLAX® OTC market achieved annual sales of approximately $555.7 million for the 52-week period ending February 22, 2025. Glenmark’s entry into this space positions it to capture a share of this high-demand market.
Marc Kikuchi, President & Business Head, North America, commented on the launch:
“We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.”
Stock movement to watch today
With Glenmark expanding its OTC portfolio in the US, market participants will be closely tracking the stock’s reaction today. Analysts expect Glenmark’s North America business to benefit from the launch, given the strong sales potential in the MiraLAX® segment.
Investors will be watching early trade trends to assess whether the stock extends gains or sees profit booking after the initial announcement-driven uptick.
Disclaimer: The views and investment recommendations in this article are sourced from official company announcements and market data. Business Upturn does not provide investment advice. Readers should consult financial experts before making any investment decisions.
